OTHER FUNCTIONS SBIR PHASE II, TOPIC 288, "RECOMBINANT ANTIBODIES AS AFFINITY CA

该项目的目标是开发针对75种癌症相关蛋白的重组抗体。在I期研究中，我们已经证明了多个抗体克隆可以从一个大型酵母展示的人类抗体库中分离出来。与杂交瘤技术获得的单克隆抗体相比，分离的抗体具有高亲和力（低nM至亚nM）和高特异性。同时，对技术平台进行了优化，以支持更强大的全长IgG显示和酵母细胞中一致的抗体表达。

The objective of this proposed project is to develop recombinant antibodies against 75 cancer-related proteins. In the Phase I study, we have demonstrated that multiple antibody clones could be isolated from a large yeast displayed human antibody library. The isolated antibodies exhibit high affinity (lOW nM to sub-nM) and high specificity compariable to monoclonal antibodies derived from hybridoma technology. In parallel, the technology platform was optimzed to support more robust full length IgG display and consistent antibody expression in yeast cells. In this proposed Phase II project, we propose to isolate antibodies against 75 cancer related antigens developed by NCI's Clinical Proteomic Technologies Initiative using AvantGn's proprietary yeast display antibody library. The isolated antibodies will be characterized in terms of affinity (on and off binding constants) and specificity, and for performance in commonly used assays such as immunoprecipitation, and/or Western blot, with the goal of identifying 2 distinct antibody clones per antigen suitable for developing ELiSAs. These antibodies will be further intergrated into proteomic research platforms in collabration with NCI's Clinical Proteomic Technologies Initiative.